Alar Irs

6.9k total citations
16 papers, 434 citations indexed

About

Alar Irs is a scholar working on General Health Professions, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Alar Irs has authored 16 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in General Health Professions, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Economics and Econometrics. Recurrent topics in Alar Irs's work include Health Systems, Economic Evaluations, Quality of Life (3 papers), Health and Medical Research Impacts (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Alar Irs is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (3 papers), Health and Medical Research Impacts (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Alar Irs collaborates with scholars based in Estonia, United Kingdom and Netherlands. Alar Irs's co-authors include Nick Freemantle, Anthony J. Hatswell, Gianluca Baio, Jesse A. Berlin, Suzanne Hill, Robyn L. Ward, Barrie Stokes, Kent Johnson, Danielle Anthony and Clare Ringland and has published in prestigious journals such as The Lancet Oncology, European Heart Journal and Neuroreport.

In The Last Decade

Alar Irs

13 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alar Irs Estonia	8	146	89	85	79	74	16	434
Anja Schiel Norway	13	124 0.8×	35 0.4×	89 1.0×	125 1.6×	17 0.2×	24	582
Frédéric Balusson France	14	56 0.4×	58 0.7×	151 1.8×	12 0.2×	28 0.4×	38	469
Robert Barrier United States	10	45 0.3×	80 0.9×	140 1.6×	14 0.2×	13 0.2×	20	447
Bernice Tsoi Canada	11	117 0.8×	32 0.4×	25 0.3×	7 0.1×	37 0.5×	29	499
Weng-Foung Huang Taiwan	16	48 0.3×	104 1.2×	22 0.3×	7 0.1×	22 0.3×	27	568
J Bruin Rugge United States	5	40 0.3×	137 1.5×	302 3.6×	15 0.2×	69 0.9×	10	588
Chao-Sung Chang Taiwan	14	25 0.2×	81 0.9×	54 0.6×	3 0.0×	26 0.4×	28	499
Nancy L. Vaught United States	7	39 0.3×	333 3.7×	186 2.2×	5 0.1×	26 0.4×	8	706
Hongjuan Yu China	18	101 0.7×	74 0.8×	88 1.0×	6 0.1×	85 1.1×	36	615
Dimple Patel United States	9	38 0.3×	64 0.7×	33 0.4×	63 0.8×	22 0.3×	20	343

Countries citing papers authored by Alar Irs

Since Specialization

Citations

This map shows the geographic impact of Alar Irs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alar Irs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alar Irs more than expected).

Fields of papers citing papers by Alar Irs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alar Irs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alar Irs. The network helps show where Alar Irs may publish in the future.

Co-authorship network of co-authors of Alar Irs

This figure shows the co-authorship network connecting the top 25 collaborators of Alar Irs. A scholar is included among the top collaborators of Alar Irs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alar Irs. Alar Irs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

DeVries, J. Hans, Alar Irs, & Hans L. Hillege. (2023). The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. European Heart Journal. 44(37). 3492–3494. 11 indexed citations

Viigimaa, Margus, Mikk Jürisson, Heti Pisarev, et al.. (2022). Effectiveness and feasibility of cardiovascular disease personalized prevention on high polygenic risk score subjects: a randomized controlled pilot study. European Heart Journal Open. 2(6). oeac079–oeac079. 7 indexed citations

Pagano, Duilio, Philip Home, Alar Irs, et al.. (2022). The path for medical associations to sponsor trustworthy guidelines: is it feasible?. Journal of the Royal Society of Medicine. 115(7). 252–256. 4 indexed citations

Hatswell, Anthony J., Gianluca Baio, Jesse A. Berlin, Alar Irs, & Nick Freemantle. (2016). Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open. 6(6). e011666–e011666. 122 indexed citations

Laius, Ott, et al.. (2015). Und soodustavate ravimite kliiniline farmakoloogia ja kasutamise suundumused Eestis. Ajakirjad. Journals by UT.

Harrison, Pille, Ott Laius, & Alar Irs. (2014). Sarnased bioloogilised ravimid. Ajakirjad. Journals by UT. 1 indexed citations

Harrison, Pille, Ott Laius, & Alar Irs. (2014). Sarnased bioloogilised ravimid – epoetiinid. Ajakirjad. Journals by UT.

Irs, Alar. (2014). Ravimite kasutusele lubamine Eestis ja Euroopa Liidus. Ajakirjad. Journals by UT.

Lass, Jana, Viveca Odlind, Alar Irs, & Irja Lutsar. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. SpringerPlus. 2(1). 124–124. 13 indexed citations

10.

Irs, Alar, et al.. (2012). Future of the European Union regulatory network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology. 76(1). 1–6. 5 indexed citations

11.

Lass, Jana, et al.. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety. 20(5). 474–481. 26 indexed citations

12.

Johnson, Kent, Clare Ringland, Barrie Stokes, et al.. (2006). Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology. 7(9). 741–746. 142 indexed citations

13.

Raal, Aіn, Krista Fischer, & Alar Irs. (2006). Determination of drug information needs of health care professionals in Estonia.. PubMed. 42(12). 1030–4. 12 indexed citations

14.

Habicht, Jarno, et al.. (2004). Health care systems in transition: Estonia. London School of Economics and Political Science Research Online (London School of Economics and Political Science). 33 indexed citations

15.

Kask, Ants, Rein Pähkla, Alar Irs, et al.. (1999). Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport. 10(4). 707–711. 57 indexed citations

16.

Pähkla, Rein, et al.. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics. 24(5). 375–380. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact